| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| License and collaboration revenue | 4,712 | 5,546 | 28,321 | 4,675 |
| Research and development | 40,003 | 37,036 | 35,893 | 35,970 |
| General and administrative | 11,130 | 10,551 | 11,738 | 10,158 |
| Total operating expenses | 51,133 | 47,587 | 47,631 | 46,128 |
| (loss) income from operations | -46,421 | -42,041 | -19,310 | -41,453 |
| Interest income | 7,049 | 7,406 | 7,573 | 7,682 |
| Other income, net | 33 | 36 | 82 | 141 |
| (loss) income before income tax benefit (expense) | -39,339 | -34,599 | -11,655 | -33,630 |
| Income tax expense (benefit) | - | 172 | - | -420 |
| Net (loss) income | -39,339 | -34,771 | -11,655 | -33,210 |
| Earnings per share, basic | -0.62 | -0.55 | -0.19 | -0.54 |
| Earnings per share, diluted | -0.62 | -0.55 | -0.19 | -0.54 |
| Weighted average number of shares outstanding, basic | 63,772,332 | 63,510,537 | 62,963,806 | 61,767,934 |
| Weighted average number of shares outstanding, diluted | 63,772,332 | 63,510,537 | 62,963,806 | 61,767,934 |
Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc (PTGX)